These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36335418)

  • 61. Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease.
    Berti A; Boukhlal S; Groh M; Cornec D
    Expert Rev Clin Immunol; 2020 Jan; 16(1):51-61. PubMed ID: 31762336
    [No Abstract]   [Full Text] [Related]  

  • 62. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    Ennis D; Lee JK; Pagnoux C
    Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis.
    Padoan R; Chieco Bianchi F; Marchi MR; Cazzador D; Felicetti M; Emanuelli E; Vianello A; Nicolai P; Doria A; Schiavon F
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3225-3227.e2. PubMed ID: 32505716
    [No Abstract]   [Full Text] [Related]  

  • 64. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
    Menzies-Gow A; Hoyte FL; Price DB; Cohen D; Barker P; Kreindler J; Jison M; Brooks CL; Papeleu P; Katial R
    Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Eosinophilic granulomatosis with polyangiitis (EGPA) and allergic bronchopulmonary mycosis (ABPM)].
    Taniguchi M; Fukutomi Y
    Nihon Rinsho; 2016 Oct; 74(10):1721-1728. PubMed ID: 30551287
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
    Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
    Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dupilumab suppresses relapsing chronic eosinophilic pneumonia with severe asthma.
    Masumoto N; Oshikata C; Nakadegawa R; Motobayashi Y; Osada R; Manabe S; Kaneko T; Tsurikisawa N
    Nagoya J Med Sci; 2023 Nov; 85(4):857-865. PubMed ID: 38155613
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
    Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
    J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.
    Mutoh T; Shirai T; Sato H; Fujii H; Ishii T; Harigae H
    Rheumatol Int; 2022 Nov; 42(11):2069-2076. PubMed ID: 34287685
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis.
    Coppola A; Flores KR; De Filippis F
    Respir Med Case Rep; 2020; 30():101050. PubMed ID: 32300522
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 75. HES and EGPA: Two Sides of the Same Coin.
    Khoury P; Akuthota P; Kwon N; Steinfeld J; Roufosse F
    Mayo Clin Proc; 2023 Jul; 98(7):1054-1070. PubMed ID: 37419574
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
    Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
    J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): an Illustrative Case and Discussion.
    Milne ME; Kimball J; Tarrant TK; Al-Rohil RN; Leverenz DL
    Curr Allergy Asthma Rep; 2022 Nov; 22(11):141-150. PubMed ID: 36103081
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Pharmacological profile of mepolizumab].
    Pauk N
    Vnitr Lek; 2023; 69(5):322-328. PubMed ID: 37827831
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?
    Menzella F; Latorre M; Ruggiero P; Bagnasco D; Heffler E
    Expert Opin Biol Ther; 2019 Jul; 19(7):601-606. PubMed ID: 31033373
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.